Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk...

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Atherosclerotic cardiovascular diseases (ASCVD) are a major global health concern.
• Statins are primary treatments for lowering low-density lipoprotein cholesterol (LDL-C) and reducing ASCVD risk.
• Some patients do not achieve guideline-recommended LDL-C targets with maximally tolerated statin doses or cannot tolerate statins.

Purpose of the Study:

• To review the evidence supporting nonstatin LDL-C lowering medications for cardiovascular risk reduction.
• To discuss practical considerations for using these agents in clinical practice.

Main Methods:

• Literature review of clinical trials and observational studies.
• Analysis of data on efficacy and safety of nonstatin therapies.
• Synthesis of current guidelines and expert recommendations.

Main Results:

• Nonstatin agents (ezetimibe, bempedoic acid, PCSK9 inhibitors) provide significant additional LDL-C lowering when used with maximally tolerated statin therapy.
• These agents have demonstrated reductions in major adverse cardiovascular events.
• Individualized treatment strategies are necessary for patients with refractory hyperlipidemia.

Conclusions:

• Nonstatin medications are valuable additions to statin therapy for patients requiring further LDL-C reduction and cardiovascular risk mitigation.
• Understanding the evidence and practical aspects of these drugs is crucial for optimizing patient care.
• These therapies offer effective options for patients unable or unwilling to intensify statin treatment.